GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)
GSK shares traded at 1,836.5p in London on 4 December, near a 52-week high, with ADRs at $48.97 in New York. The stock is up about 50% from its 2024 low, following strong Q3 results, upgraded 2025 guidance, and easing litigation risk. Investors are watching upcoming FDA decisions and a CEO change set for 1 January 2026.